{"id":"W3082708938","doi":"10.2217/fon-2020-0586","title":"Avelumab and Axitinib Combination Therapy for the Treatment of Advanced Renal Cell Carcinoma","year":2020,"lang":"en","type":"review","venue":"Future Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Pfizer","keywords":"Nivolumab; Axitinib; Avelumab; Medicine; Ipilimumab; Renal cell carcinoma; Oncology; Internal medicine; Immunotherapy; Combination therapy; Cabozantinib; Tyrosine-kinase inhibitor; Targeted therapy; Sunitinib; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009368095,0.0004505155,0.002157306,0.00009607081,0.00008248715,0.000006910435,0.0001151252,0.0004110331,0.00004479018],"category_scores_gemma":[0.00001275342,0.0002379334,0.0005898584,0.0001482885,0.0001065298,0.00001670763,0.00002078717,0.0001897003,0.000007494891],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000615343,"about_ca_system_score_gemma":0.0006745474,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001109352,"about_ca_topic_score_gemma":0.000007586782,"domain_scores_codex":[0.9984397,0.0001671126,0.0005347077,0.0004583634,0.0001596777,0.0002404095],"domain_scores_gemma":[0.9981688,0.0007027911,0.0005112401,0.0003834904,0.0001098017,0.0001239151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005710452,0.0006778536,0.000007276368,0.002777051,0.0003382465,0.00008602501,0.0004395945,7.265332e-8,0.00002217636,0.0002369841,0.000626862,0.9942168],"study_design_scores_gemma":[0.007274697,0.02285585,0.000279578,0.0003016471,0.002332824,0.0001990838,0.0001240641,0.000004644305,0.0002281531,0.00001714689,0.9662263,0.0001559736],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00103666,0.9907619,0.0000113747,0.001027105,0.0004817741,0.00517405,0.0001100879,0.00002127422,0.001375791],"genre_scores_gemma":[0.001107711,0.9946151,0.0006757405,0.00009812394,0.000973961,0.001235119,0.0005248513,0.00006468182,0.0007047179],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9940608,"threshold_uncertainty_score":0.9702644,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04777237359308242,"score_gpt":0.3457187380641106,"score_spread":0.2979463644710282,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}